Addressing challenges through the rigorous application of science
Our platform creates high-quality, affordable RNA at scale
Messenger RNA for human health
Sustainable food production through RNA solutions
Scaling biology in the service of humanity
A diverse, compassionate, and qualified team
Working at GreenLight
Collaborating with GreenLight
RNA can help tackle some of humanity’s greatest problems
Our product pipeline is sustainable by design and produced in a responsible manner.
Our business model aims to improve lives across all geographies.
One of the world’s first publicly traded public benefit corporations
Sign-up for our Newsletter
IN THE PIPELINE
Messenger RNA’s features make it broadly valuable for human health. It is well known that mRNA is being used to make effective Covid-19 vaccines that have been developed quickly—critical for pandemic response. GreenLight is working on multiple vaccines and therapeutic uses of mRNA.
Our Covid-19 mRNA vaccine product is in development. We envision a global network of modular manufacturing units that would allow us to commercially produce more than one billion vaccine doses annually, meeting local demand through local production.
Read more
Many genetic diseases have no permanent cure. For example, current treatments for sickle cell disease focus on managing pain and other effects, such as anemia. These treatment regimens are costly, invasive, and impractical. Our RNA-based gene therapy is capable of delivering a healthy copy of the gene to stem cells.
We are currently working on early stage development of monoclonal antibodies as a modality.
Messenger RNA can be used for both vaccines and therapies.
Simple changes to the messenger RNA molecule allow us to make new products quickly.
BECOME A PARTNER
We work with some of the world’s leading universities, companies, and scientists
Learn more
The latest on GreenLight’s work and partnerships, and what the world has been saying about us.
03.09.23
03.07.23
03.01.23
02.01.23
01.09.23
11.09.22